872 related articles for article (PubMed ID: 12214145)
21. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
Wegert W; Harder S; Bassus S; Kirchmaier CM
Platelets; 2005 Feb; 16(1):45-50. PubMed ID: 15763896
[TBL] [Abstract][Full Text] [Related]
22. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
[TBL] [Abstract][Full Text] [Related]
23. History of rFVIIa therapy.
Hedner U
Thromb Res; 2010 Apr; 125 Suppl 1():S4-6. PubMed ID: 20188400
[TBL] [Abstract][Full Text] [Related]
24. NovoSeven: mode of action and use in acquired haemophilia.
Von Depka M
Intensive Care Med; 2002 Oct; 28 Suppl 2():S222-7. PubMed ID: 12404090
[TBL] [Abstract][Full Text] [Related]
25. Recombinant activated factor VII as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
[TBL] [Abstract][Full Text] [Related]
26. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.
Hedner U; Ezban M
Annu Rev Med; 2008; 59():29-41. PubMed ID: 17845136
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.
Dargaud Y; Prevost C; Lienhart A; Claude Bordet J; Negrier C
Haemophilia; 2011 Nov; 17(6):957-61. PubMed ID: 21453422
[TBL] [Abstract][Full Text] [Related]
28. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
29. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
30. Recombinant activated factor VII: 30 years of research and innovation.
Hedner U
Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
[TBL] [Abstract][Full Text] [Related]
31. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
Campbell RA; Fischer TH; Wolberg AS
Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
[TBL] [Abstract][Full Text] [Related]
32. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
33. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
34. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay.
Antovic JP; Antovic A
Thromb Haemost; 2003 Oct; 90(4):620-7. PubMed ID: 14515182
[TBL] [Abstract][Full Text] [Related]
35. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
36. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
Li R; Panckeri KA; Fogarty PF; Diamond SL
Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576
[TBL] [Abstract][Full Text] [Related]
37. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
[TBL] [Abstract][Full Text] [Related]
38. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
[TBL] [Abstract][Full Text] [Related]
39. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
[TBL] [Abstract][Full Text] [Related]
40. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
Hedner U; Erhardtsen E
Ann Med; 2000 Dec; 32 Suppl 1():68-72. PubMed ID: 11209985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
